{"id":"NCT00366678","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","briefTitle":"Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants","officialTitle":"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in France.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-10","primaryCompletion":"2008-11","completion":"2008-11","firstPosted":"2006-08-21","resultsPosted":"2012-08-15","lastUpdate":"2012-08-15"},"enrollment":613,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Vaccines, Pneumococcal"],"interventions":[{"type":"BIOLOGICAL","name":"13-valent pneumococcal conjugate vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"7-valent pneumococcal conjugate vaccine","otherNames":[]},{"type":"DRUG","name":"Pentavac","otherNames":[]}],"arms":[{"label":"13-valent pneumococcal conjugate vaccine","type":"EXPERIMENTAL"},{"label":"7-valent pneumococcal conjugate vaccine","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with routine pediatric vaccines in France.","primaryOutcome":{"measure":"Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria, Tetanus, Hemophilus Influenza Type b (Hib), Poliomyelitis (Type 1, 2, 3), Pertussis Toxin (PT) and Filamentous Hemagglutinin (FHA) in 13vPnC Group Relative to 7vPnC Group","timeFrame":"One Month After the 3-Dose Infant Series (at 5 months of age) and the Toddler Dose (at 13 months of age)","effectByArm":[{"arm":"13vPnC After the Infant Series","deltaMin":100,"sd":null},{"arm":"7vPnC After the Infant Series","deltaMin":100,"sd":null},{"arm":"13vPnC After the Toddler Dose","deltaMin":100,"sd":null},{"arm":"7vPnC After the Toddler Dose","deltaMin":100,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG002 vs OG003","p":null}]},"eligibility":{"minAge":"42 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":null},"locations":{"siteCount":45,"countries":["France"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":304},"commonTop":["Erythema (Any)","Irritability","Erythema (Mild)","Induration (Any)","Tenderness (Any)"]}}